Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

on and $0.4 million for the nine months ended September 30, 2007 and 2006, respectively. During the nine months ended June 30, 2007, the Company recognized $0.8 million of interest income associated with its investments and a $2.8 million reduction in non-cash interest expense for the net decrease in the fair value of warrants issued in connection with the February and June 2007 financings.

The foreign exchange loss was $1.3 million for the nine months ended September 30, 2007, compared to $1.7 million for the corresponding period in 2006. The decrease in 2007 was due to a lower inter-company loan balance and more stable spreads between the value of the U.S. dollar and the Euro compared to the prior year as the dollar denominated inter-company loan between the Company's subsidiaries is revalued each quarter based on changes in the value of the dollar versus the Euro, with all related changes recognized in earnings.

Net loss for the nine months ended September 30, 2007 was $15.4 million, compared to a net loss of $17.5 million in the corresponding period in 2006. Basic and diluted net loss per share was $0.78 in the nine months ended September 30, 2007, on 19.7 million weighted average shares outstanding, compared to basic and diluted net loss per share of $1.31 in the nine months ended September 30, 2006, on 13.4 million weighted average shares outstanding.

L-MTP-PE Regulatory Status

The L-MTP-PE New Drug Application (NDA) includes efficacy and safety data from 678 patients with non-metastatic resectable osteosarcoma, 332 of whom received L-MTP-PE, and from 115 patients with metastatic or unresectable osteosarcoma, 39 of whom received L-MTP-PE, in the controlled Phase 3 trial conducted by the Pediatric Oncology Group (POG) and the Children's Cancer Group (CCG), now the Children's Oncology Group (COG), sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. Also included are safety and efficacy data from 51
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance ... reducing the costs of an auto insurance policy . , ... lower prices for their vehicle insurance policies. The safety a vehicle ... costs. Because of this, drivers should always carry a first ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Nov. 1 To mark the start of,American Diabetes ... to adopt healthy habits that may help them to ... disease that affects an estimated 21 million,Americans including more ... serious, public health concern with causes linked to,both genetics ...
... Minn., Nov. 1 Otter Tail,Corporation (Nasdaq: OTTR ) announced ... highlights: -- Record third quarter revenues of $302.2 million. ... of 2007 compared with $13.5 million for ... of $0.44 for the third quarter of 2007 ...
... Edwards Lifesciences,Corporation (NYSE: EW ), a ... cardiovascular disease, is scheduled to participate in the,Southern ... Newport,Beach, California on Wednesday, November 7, 2007. ... Investor,Relations, is scheduled to speak to conference attendees ...
... HAYWARD, Calif., Nov. 1 Acologix, Inc., a ... Dawn,McGuire, M.D. as its Chief Medical Officer. As ... of executive leadership in drug,development, including roles as ... McGuire brings substantial expertise in therapeutic,product development for ...
... 1 Thousands of public,health professionals will meet ... and address the nation,s most pressing public health ... Annual Meeting., The five-day meeting of more ... is expected to draw around 14,000,public health researchers, ...
... Nov. 1 Vital Images, Inc.,(Nasdaq: VTAL ), ... will present at the CIBC World,Markets 18th Annual Healthcare ... a.m. ET). Jay D. Miller, president and chief executive,officer, ... To access the Webcast, go to the investors, section ...
Cached Medicine News:Health News:Health Secretary Promotes Awareness of Diabetes, Urges Healthy Habits 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 3Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 4Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 5Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 6Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 7Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 8Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 9Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 10Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 11Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 12Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 13Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 14Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 15Health News:Edwards Lifesciences to Present at the Southern California Investor Conference 2Health News:Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer 2Health News:Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer 3Health News:14,000 Public Health Experts to Convene at American Public Health Association Annual Meeting in Washington, D.C. 2Health News:14,000 Public Health Experts to Convene at American Public Health Association Annual Meeting in Washington, D.C. 3Health News:Vital Images to Present at the CIBC World Markets 18th Annual Healthcare Conference on Wednesday, November 7 2
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ --,Nuvelo, Inc. ... data from the Anthem (Anticoagulation with rNAPc2,To Help ... June,26th issue of the Journal of of Cardiology ... 7.5 mcg/kg) recombinant,nematode anticoagulant protein c2 (rNAPc2) reduced ...
... June 15 /CNW/ - Today AMADEO, one of the,first ... receptor blockers in hypertensive patients with,diabetic nephropathy, was ... results from this study show that ,telmisartan reduces proteinuria ... , ,Commenting on the results, ...
Cached Medicine Technology:Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 2Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 3Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5
... Designed in collaboration with Dr. George ... the Ojemann Cortical Stimulator is the ... procedures. This portable, constant current unit ... settings suitable for use in the ...
... Integra Epilepsy cortical strip electrodes are ... intracranial placement through a burr hole. ... tunneling and enables quick and secure ... Like all Integra Epilepsy electrode designs, ...
...
... URISYS 2400 is designed for laboratories looking ... and convenience in system operation in terms ... and extended calibration and on-board stability., ... system providing enhanced walk-away capability for medium ...
Medicine Products: